Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-11-07
2008-11-04
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S534000, C560S037000
Reexamination Certificate
active
07446128
ABSTRACT:
A compound which can be used as an agent for treating interstitial cystitis. An agent for treating interstitial cystitis, which comprises a phenoxyacetic acid derivative represented by a general formula (I)wherein R1represents hydroxyl group or a lower alkoxy group, or a pharmacologically acceptable salt thereof. Since the phenoxyacetic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof has a selective β3-adrenoceptor stimulating activity and a remarkable action to inhibit a capsaicin-sensitive sensory nerve, it can be used as a preventive or therapeutic agent for interstitial cystitis and hyperactive bladder which are accompanied by pain, other diseases in which the capsaicin-sensitive sensory nerve is concerned (e.g., acute or chronic and systemic or topical pain and inflammation) and irritable bowel syndrome (IBS) and the like.
REFERENCES:
patent: 6538152 (2003-03-01), Tanaka et al.
patent: 2004/0138252 (2004-07-01), Ikeda et al.
patent: 2004/0229947 (2004-11-01), Yamazaki et al.
patent: 1 095 932 (2001-05-01), None
patent: 1 405 638 (2004-04-01), None
patent: 1 426 355 (2004-06-01), None
patent: WO 00/02846 (2000-01-01), None
patent: WO 03/006019 (2003-01-01), None
patent: WO 03/024916 (2003-03-01), None
patent: WO 2004/098586 (2004-11-01), None
Shigeru Itabashi, et al.; Evidence that an atypical β-adrenoceptor mediates the prejunctional inhibition of non-adrengeric non-cholinergic contraction in guinea-pig bronchi; European Journal of Pharmacology, vol. 218, 1992, p. 187-190.
Diagnosis of interstitial cystitis; Urinary Disturbance Practice vol. 12, No. 1. 2004 p. 30-37.
Interstitial cystitis and C-fiber; Urinary Disturbance Practice vol. 12; No. 2004; p. 50-57.
The Merck Index; 1989; pp. 1355, 1359 and 1360.
Prematurity: Problems in Newborns: Merck Manual Home Edition, no date, pp. 1 to 3.
The Journal of Urology; Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, Aug. 28-29, 1987; pp. 203-206.
Hanno et al., “The Diagnosis of Interstitial Cystitis Revisited: Lessons Learned from the National Institutes of Health Interstitial Cystitis Database; Study” The Journal of Urology, Feb. 1999, vol. 161, pp. 553-557.
Akahane Satoshi
Kaidoh Kouichi
Kissei Pharmaceutical Co. Ltd.
Oh Taylor Victor
Sughrue & Mion, PLLC
LandOfFree
Agent for treating interstitial cystitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for treating interstitial cystitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treating interstitial cystitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4039490